Maravai Lifesciences Holdings (MRVI) Non-Current Assets (2020 - 2026)
Maravai Lifesciences Holdings (MRVI) posted quarterly Non-Current Assets of $461.5 million for Q1 2026, down 20.91% year-over-year from $583.5 million in Q1 2025, and down 2.71% quarter-over-quarter from $474.3 million in Q4 2025.
Maravai Lifesciences Holdings (MRVI) Non-Current Assets (2020 - 2026) Analysis & Trends
Maravai Lifesciences Holdings' Non-Current Assets history runs 7 years deep, the most recent figure standing at $461.5 million for Q1 2026.
- In Q1 2026, Non-Current Assets fell 20.91% year-over-year to $461.5 million; the TTM figure through Mar 2026 stood at $2.0 billion (down 20.9% YoY), while the FY2025 annual figure was $474.3 million, down 18.09% from the prior year.
- Non-Current Assets for Q1 2026 stood at $461.5 million, down from $474.3 million in the prior quarter.
- The five-year high for Non-Current Assets was $1.6 billion in Q3 2023, with the low at $461.5 million in Q1 2026.
- The 5-year median for Non-Current Assets is $776.8 million (2024), against an average of $967.7 million.
- The sharpest annual moves came in 2022 and 2024: Non-Current Assets jumped 53.75% in 2022, then plunged 61.76% in 2024.
- Maravai Lifesciences Holdings' Non-Current Assets stood at $1.4 billion in 2022, then sank by 45.1% to $787.5 million in 2023, then slipped by 26.47% to $579.1 million in 2024, then retreated by 18.09% to $474.3 million in 2025, then slipped by 2.71% to $461.5 million in 2026.
- Business Quant data shows MRVI's Non-Current Assets at $461.5 million in Q1 2026, $474.3 million in Q4 2025, and $523.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Maravai Lifesciences Holdings | 1.48 Bn | 1.56 Bn | 20.65 Mn | 448.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 448.09 Mn |
| Mar 31, 2026 | 461.48 Mn |
| Dec 31, 2025 | 474.33 Mn |
| Sep 30, 2025 | 523.32 Mn |
| Jun 30, 2025 | 537.21 Mn |
| Mar 31, 2025 | 583.47 Mn |
| Dec 31, 2024 | 579.10 Mn |
| Sep 30, 2024 | 599.12 Mn |
| Jun 30, 2024 | 762.25 Mn |
| Mar 31, 2024 | 776.76 Mn |
| Dec 31, 2023 | 787.54 Mn |
| Sep 30, 2023 | 1.57 Bn |
| Jun 30, 2023 | 1.57 Bn |
| Mar 31, 2023 | 1.55 Bn |
| Dec 31, 2022 | 1.43 Bn |
| Sep 30, 2022 | 1.41 Bn |
| Jun 30, 2022 | 1.41 Bn |
| Mar 31, 2022 | 1.42 Bn |
| Dec 31, 2021 | 1.18 Bn |
| Sep 30, 2021 | 1.21 Bn |